All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Measurable residual disease (MRD) measurement is performed to assess response to treatment and serves as an independent prognostic indicator in patients with acute myeloid leukemia (AML). Along with the assessment of clinical, cytogenetic and molecular data assessed at diagnosis, it is important in planning treatment and for risk stratification. A number of assays have been established for several recurrent leukemic markers.1,2
Internal tandem duplications in the FLT3 gene (FLT3-ITDs) are commonly recognized as poor prognostic markers in AML. However, their heterogeneity makes conventional PCR methods laborious or intensive.3 Therefore, novel methods to detect FLT3-ITD are needed to improve monitoring of these high-risk patients.
In their letter to the editor, Tamara J. Blätte, Department of Hematology, Charité University Medicine, Berlin, DE, and colleagues developed a method4 based on targeting high-coverage NGS using a two-step PCR to amplify and sequence the affected FLT3 exons. The team also developed an open-source analysis software program, getITD. The team sequenced three human AML cell lines, two healthy volunteers, and 57 samples from 28 AML patients, in the AMLSG BiO study (NCT 01252485).
The team found getITD to accurately and precisely detect ITDs at broad range of lengths, insertion sites and VAFs. The maximum detectable ITD read length of the assay is currently 250 bp with a minimum insert length of 6 bp. As the method does not require manual analysis it can be applied to routine clinical monitoring. The open source software can be found online.
This technique has increased sensitivity in comparison to conventional FA, which could be increased further by analyzing more than 50ng of sample DNA, however the researchers determine that closer patient monitoring would be better suited to enable earlier MRD detection. Using getITD, ITD lengths, integration sites and sequences can all be identified in one assay, which allow for better monitoring of separate ITD clones within a sample.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox